BiotechTube
Bora Pharmaceuticals

Bora Pharmaceuticals

6472.TWPre-clinical
borapharm.com

Bora Pharmaceuticals is a major player in the Taiwanese pharmaceutical industry, operating as both a CDMO and a commercial-stage drug company. It has built a significant valuation through its manufacturing capabilities and product portfolio, which includes a range of generic and proprietary medicines. The company's strategic position leverages Taiwan's strong manufacturing ecosystem to serve both domestic and international pharmaceutical markets.

Market Cap
$1.8B
-30.6% period
Pipeline
—
Patents
—
Publications
8
indexed

6472.TW · Stock Price

USD 453.50199.95 (-30.60%)

Historical price data

AI Company Overview

Bora Pharmaceuticals is a major player in the Taiwanese pharmaceutical industry, operating as both a CDMO and a commercial-stage drug company. It has built a significant valuation through its manufacturing capabilities and product portfolio, which includes a range of generic and proprietary medicines. The company's strategic position leverages Taiwan's strong manufacturing ecosystem to serve both domestic and international pharmaceutical markets.

Biotech

Technology Platform

Integrated contract development and manufacturing organization (CDMO) platform offering formulation development, analytical services, and commercial-scale manufacturing for solid and semi-solid dosage forms, compliant with international regulatory standards.

Opportunities

Growth is driven by the expanding global CDMO market, supply chain diversification trends favoring Taiwan, and rising demand for generic medicines in aging Asian populations.
The company can leverage its integrated model to capture both service and product-based revenue.

Risk Factors

Key risks include intense pricing pressure in generics, regulatory compliance challenges in manufacturing, potential client concentration in the CDMO business, and geopolitical tensions associated with its Taiwan base.

Competitive Landscape

Competes with global CDMOs (Lonza, Catalent) and generic pharma companies (Teva, Viatris), as well as regional Taiwanese firms. Differentiation stems from its integrated business model, Taiwanese manufacturing base offering quality and strategic location, and focus on complex generics and contract services.